Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:AAL
NasdaqGS:AALAirlines

Is American Airlines Group (AAL) Pricing Look Attractive After Recent Share Price Rebound

Wondering whether American Airlines Group at US$14.64 is a bargain or a value trap? This article walks through the key facts so you can judge the stock's price tag with more confidence. The stock has returned 5.7% over the last 7 days and 23.6% over the last 30 days. Year to date it is down 5.4%. The 5 year return shows a decline of 39.8%, with a 28.3% return over the last year and a 1.5% decline over 3 years. Recent coverage of American Airlines Group has focused on ongoing industry wide...
NYSE:ICE
NYSE:ICECapital Markets

Is ICE’s Record Energy OI and GPU Futures Push Altering The Investment Case For Intercontinental Exchange (ICE)?

In May 2026, Intercontinental Exchange, Inc. reported record open interest and liquidity across its global natural gas and power markets, alongside regulatory approvals for ICE ETF Hub expansion in Europe and Australia and plans to introduce GPU compute futures with Ornn, further broadening its trading and data infrastructure footprint. These developments highlight how ICE is deepening its role in critical energy hedging and emerging GPU compute benchmarks while extending ETF primary market...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

How Investors May Respond To DexCom (DXCM) Global App Recalls Over Delayed Glucose Alerts

In April 2026, Dexcom voluntarily initiated Class II global recalls of its G7, ONE and ONE+ iOS and watchOS CGM apps after an FDA enforcement report highlighted a software defect that could delay real-time glucose readings and alerts, increasing the risk of users relying on outdated data to manage hypoglycemia or hyperglycemia. This recall underscores how even a low-level software issue in widely distributed digital health tools can quickly become a material patient-safety and...
NYSE:STE
NYSE:STEMedical Equipment

Is It Time To Reconsider STERIS (STE) After Recent Share Price Weakness?

If you are wondering whether STERIS at around US$212 a share offers good value or if you are better off waiting on the sidelines, this article walks through what the current price might be implying. The stock has been weak recently, with the share price down about 1.8% over the last week, 0.8% over the last month, 14.9% year to date and 12.4% over the past year. These moves may change how you view its risk and reward trade off. Recent coverage around STERIS has focused on its role within...
NasdaqGM:FUTU
NasdaqGM:FUTUCapital Markets

Why Futu Holdings (FUTU) Is Up 15.9% After Booking a Major Regulatory Penalty and Profit Drop

In the past week, Futu Holdings reported Q1 2026 results showing revenue rising to HK$5,855.99 million while net income fell to HK$850.55 million after fully reflecting a proposed RMB1.85 billion regulatory penalty from Chinese authorities over alleged unlicensed activities in mainland China. Despite the earnings impact of the proposed China Securities Regulatory Commission fine, Futu’s funded accounts grew 34% year over year to 3.59 million, with mainland China now representing about 13% of...
NasdaqGS:WDC
NasdaqGS:WDCTech

Western Digital’s Post Quantum Drives Put AI Storage Story In Focus

Western Digital (NasdaqGS:WDC) has introduced high-capacity hard drives that integrate post-quantum cryptography to secure AI-era data infrastructure. The new drives apply NIST-approved, quantum-resilient security standards directly in storage hardware to address long-term data protection risks. The launch targets enterprise and cloud environments where AI workloads generate sensitive, long-lived data sets. Western Digital is bringing this step into the spotlight at a time when its stock...
NasdaqGS:DYN
NasdaqGS:DYNBiotechs

Dyne Therapeutics (DYN) Is Up 11.3% After FDA BLA Filing For DMD Drug Candidate Zeleciment Rostudirsen

Dyne Therapeutics has submitted a Biologics License Application to the FDA for zeleciment rostudirsen (DYNE-251) seeking Accelerated and Priority Review to treat Duchenne muscular dystrophy patients amenable to exon 51 skipping, based on Phase 1/2 DELIVER data showing increased dystrophin production, functional gains and a favorable safety profile. This filing, together with the ongoing Phase 3 FORZETTO confirmatory trial and a broader exon-skipping pipeline, positions Dyne as a potential...
TSE:4568
TSE:4568Pharmaceuticals

Daiichi Sankyo Expands Vanflyta Access As Oncology Data Shapes Growth Story

Daiichi Sankyo (TSE:4568) has secured public reimbursement in Quebec, Canada for its targeted acute myeloid leukemia treatment Vanflyta. The change expands access for certain patients with FLT3-ITD positive acute myeloid leukemia within the province’s public healthcare system. The company is also preparing to present more than 25 oncology abstracts, including pivotal trial updates, at the 2026 ASCO Annual Meeting. Daiichi Sankyo, known for its oncology and cardiovascular portfolio, is...
NYSE:AXP
NYSE:AXPConsumer Finance

Is It Time To Reassess American Express (AXP) After Recent Share Price Swings?

Wondering if American Express at around US$316 per share is giving you fair value for the risk you are taking, or if the current price is out of line with what you are actually getting. The stock has gained 1.5% over the past week, softened around 1.0% over the last month, is down 15.1% year to date, yet shows an 8.8% return over the past year and has more than doubled over 5 years. Recent headlines have focused on American Express as a major player in payments and card services. This often...
SWX:NOVN
SWX:NOVNPharmaceuticals

Assessing Novartis (SWX:NOVN) Valuation As Shares Cool After Strong Multi Year Returns

Recent share performance and basic snapshot Novartis (SWX:NOVN) has seen mixed share performance recently, with the stock down over the past week but higher over the past month, and its total return over the past year above 25%. The company has a market value of about CHF 224.8b, with revenue of $56,578.0m and net income of $13,534.0m from its pharmaceutical operations across cardiovascular, immunology, neuroscience, oncology, and hematology therapies. See our latest analysis for Novartis. At...
NYSE:KMI
NYSE:KMIOil and Gas

Has Kinder Morgan (KMI) Share Price Weakness Opened A Potential Opportunity For Investors?

If you are wondering whether Kinder Morgan's share price still offers value at around US$31.08, it helps to first line up what the current valuation is actually telling you. The stock is up 12.2% year to date and 15.4% over the past year, even though it has fallen 8.0% over the last week and 4.5% over the past month. This can change how the market is weighing its risks and rewards. Recent headlines have highlighted Kinder Morgan's role as a major energy infrastructure provider in the US,...
ENXTPA:ELIS
ENXTPA:ELISCommercial Services

Assessing Whether Elis (ENXTPA:ELIS) Still Looks Undervalued After Its Recent Share Price Move

Elis (ENXTPA:ELIS) is back on investors’ radar after its recent share price move, with the stock now around €27.12 and short term returns offering a fresh snapshot of market sentiment. See our latest analysis for Elis. Recent trading reflects a steady trend, with a 1-day share price return of 1.57% at €27.12 and a year to date share price return of 13.85%. The 5 year total shareholder return of 95.83% points to solid longer term compounding. For investors interested in this kind of steady...
ASX:MQG
ASX:MQGCapital Markets

Is Macquarie Group (ASX:MQG) Price Reflecting Its Capital Markets Strength Or Too Much Optimism

If you are wondering whether Macquarie Group at around A$238.55 is offering good value or asking too much, the starting point is to get clear on what the current price is really implying. The stock is roughly flat over the past week with a 0.7% decline, while returns of 1.5% over 30 days, 17.1% year to date and 14.9% over 1 year give useful context before looking at any valuation metrics. Recent coverage has focused on Macquarie Group's position in capital markets and its role across asset...
NYSE:VICI
NYSE:VICISpecialized REITs

Is VICI Properties (VICI) Offering Value After Trailing Specialized REIT Peers This Year?

Wondering if VICI Properties at US$28.22 is a bargain or a trap? This article walks through what the current price might be implying about the stock's value. The share price is roughly flat year to date with a 0.2% gain, but has declined 1% over the last week and 1.3% over the past month, while the return over the last year is down 5.5%. Recent headlines around VICI Properties have focused on how the stock has trailed the broader Specialized REITs peer group over the last year, reinforcing...